Cargando…

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors

SIMPLE SUMMARY: Ovarian cancer treatment is the deadliest of gynecological cancers but the introduction of target therapies in its therapeutic algorithm has significantly improved outcomes. The aim of this article was to provide a review of completed and ongoing clinical trials involving the use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nero, Camilla, Ciccarone, Francesca, Pietragalla, Antonella, Duranti, Simona, Daniele, Gennaro, Salutari, Vanda, Carbone, Maria Vittoria, Scambia, Giovanni, Lorusso, Domenica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999042/ https://www.ncbi.nlm.nih.gov/pubmed/33803954 http://dx.doi.org/10.3390/cancers13061298

Ejemplares similares

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment
por: Nero, Camilla, et al.
Publicado: (2021)

Immunotherapy in gynecological cancers
por: Lorusso, Domenica, et al.
Publicado: (2021)

PTEN and Gynecological Cancers
por: Nero, Camilla, et al.
Publicado: (2019)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
por: Agostinelli, Veronica, et al.
Publicado: (2023)

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
por: Nero, Camilla, et al.
Publicado: (2021)

Integrating a Comprehensive Cancer Genome Profiling into Clinical Practice: A Blueprint in an Italian Referral Center
por: Nero, Camilla, et al.
Publicado: (2022)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Conservatively treated glassy cell carcinoma of the cervix
por: Ferrandina, Gabriella, et al.
Publicado: (2008)

Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials
por: Duranti, Simona, et al.
Publicado: (2021)

Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives
por: Giustozzi, Alessandra, et al.
Publicado: (2021)

Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
por: Musacchio, L., et al.
Publicado: (2022)

Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital
por: Bizzarri, Nicolò, et al.
Publicado: (2021)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

The Role of Artificial Intelligence in Managing Multimorbidity and Cancer
por: Cesario, Alfredo, et al.
Publicado: (2021)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

Efficacy and safety of PARP inhibitors in elderly patients with advanced ovarian cancer: a systematic review and meta-analysis
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
por: Banerjee, Susana, et al.
Publicado: (2020)

Immune Check Point Inhibitor–Associated Glomerulonephritis
por: Ashour, Tarek, et al.
Publicado: (2018)

Immune Check Point Inhibitor–Associated Endothelialitis
por: Bobart, Shane A., et al.
Publicado: (2020)

PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016)

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells
por: Morra, Francesco, et al.
Publicado: (2017)

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
por: Prados-Carvajal, Rosario, et al.
Publicado: (2021)

PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective
por: Loizzi, Vera, et al.
Publicado: (2020)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Dual Inhibitors of PARPs and ROCKs
por: Antolín, Albert A., et al.
Publicado: (2018)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?
por: Heym, Peter-Paul, et al.
Publicado: (2012)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
por: Wang, Luyao, et al.
Publicado: (2017)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
por: Maluchenko, Natalya, et al.
Publicado: (2022)

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021)

Immune Check Point Inhibitors Triggering Non Autoimmune Polyendocrinopathy
por: Vergne-Santiago, Norma, et al.
Publicado: (2021)

FRI332 Check Point Inhibitor Induced Hypophysitis/Hypopituitarism
por: Chandpuri, Ranjit Singh
Publicado: (2023)

Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors
por: Hammel, Pascal, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_atkl2f191l8k29sr1basfq387d